Jose M Munita, Samuel L Aitken, William R Miller, Federico Perez, Rossana Rosa, Luis A Shimose, Paola N Lichtenberger, Lilian M Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A Bonomo, Cesar A Arias
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
March 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America